<ul>
<li>3 只生物科技股票可能受益于专利悬崖</li>
</ul>
<p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免费报告) - Brookline Capital Markets 的股票研究分析师在 5 月 5 日星期二发布的研究报告中下调了对 CRISPR Therapeutics 2028 财年的每股收益预期。Brookline Capital Markets 分析师 L. Cann 现在预测该公司将发布每股收益 6.91 美元，低于之前预测的 7.44 美元。CRISPR Therapeutics 当前全年的共识预期为每股亏损 4.93 美元。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<p>CRISPR Therapeutics (NASDAQ:CRSP - 获取免费报告) 最近在 5 月 5 日星期二发布了季度财报。该公司报告季度每股亏损 1.28 美元，低于分析师共识预期的每股亏损 1.22 美元，差额为 0.06 美元。该季度的收入为 146 万美元，而分析师预期为 606 万美元。CRISPR Therapeutics 的股本回报率为负 25.53%，净利润率为负 13,856.54%。与去年同期相比，该季度的收入增长了 68.6%。在去年同期，该公司每股亏损 1.58 美元。</p>
<ul>
<li>CRISPR Therapeutics 在财报后上涨，管线希望增加</li>
</ul>
<p>其他一些券商最近也对 CRSP 发表了评论。Piper Sandler 在 3 月 17 日星期二的研究报告中重申了 “增持” 评级，并将 CRISPR Therapeutics 的目标价从 105.00 美元上调至 110.00 美元。美国银行在 1 月 22 日星期四的研究报告中将 CRISPR Therapeutics 的目标价从 90.00 美元下调至 89.00 美元，并对该股票给予 “买入” 评级。Citizens Jmp 在 1 月 30 日星期五的研究报告中将 CRISPR Therapeutics 的目标价从 86.00 美元下调至 80.00 美元，并对该股票给予 “市场表现优于大盘” 评级。TD Cowen 在 2 月 13 日星期五的研究报告中将 CRISPR Therapeutics 的目标价从 40.00 美元上调至 45.00 美元，并给予该股票 “持有” 评级。最后，摩根士丹利在 2 月 17 日星期二的研究报告中重申了 “减持” 评级，并将 CRISPR Therapeutics 的目标价设定为 33.00 美元。一位投资分析师对该股票给予了强烈买入评级，十位给予买入评级，六位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，CRISPR Therapeutics 目前的共识评级为 “适度买入”，共识目标价为 64.53 美元。</p>
<p><strong>阅读我们关于 CRSP 的最新研究报告</strong></p>
<h2>CRISPR Therapeutics 价格表现</h2>
<ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
<p>CRSP 股票在星期三开盘价为 52.38 美元。该股票的 50 日移动平均线为 52.41 美元，200 日移动平均线为 54.60 美元。该股票的市值为 50.5 亿美元，市盈率为 -8.42，贝塔值为 1.74。CRISPR Therapeutics 的 12 个月低点为 33.03 美元，12 个月高点为 78.48 美元。</p>
<h2>CRISPR Therapeutics 的内部交易</h2>
<p>在相关消息中，首席法律顾问 James R. Kasinger 于 3 月 23 日星期一出售了 3,182 股公司的股票。股票以平均价格 46.78 美元出售，总价值为 148,853.96 美元。出售完成后，首席法律顾问直接持有公司 94,308 股股票，价值 4,411,728.24 美元。此次交易使其持股减少了 3.26%。该出售在与证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Samarth Kulkarni 于 3 月 23 日星期一出售了 10,020 股公司的股票。股票以平均价格 46.78 美元出售，总价值为 468,735.60 美元。出售完成后，首席执行官直接持有公司 255,501 股股票，价值约 11,952,336.78 美元。这代表其持股减少了 3.77%。该出售的 SEC 备案提供了更多信息。在过去的九十天里，内部人士已出售 51,828 股公司股票，价值 2,578,097 美元。当前 4.10% 的股票由内部人士持有。</p>
<h2>对 CRISPR Therapeutics 的对冲基金看法</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Mcguire Capital Advisors Inc. 在第四季度购买了价值约 25,000 美元的 CRISPR Therapeutics 新头寸。Ramirez Asset Management Inc. 在第四季度购买了价值约 26,000 美元的 CRISPR Therapeutics 新头寸。Rothschild Investment LLC 在第四季度将其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 现在拥有 562 股公司股票，价值 29,000 美元，此前在上个季度购买了额外的 502 股。Thurston Springer Miller Herd &amp; Titak Inc. 在第四季度将其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc. 现在拥有 576 股公司股票，价值 30,000 美元，此前在上个季度购买了额外的 382 股。最后，Optiver Holding B.V. 在第三季度将其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V. 现在拥有 504 股公司股票，价值 33,000 美元，此前在上个季度购买了额外的 210 股。69.20% 的股票由机构投资者持有。</p>
<h2>关于 CRISPR Therapeutics</h2>
<p>(获取免费报告)</p>
<p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术对人类细胞中的基因进行修改，旨在为一系列严重疾病创造持久的治疗方案。其研发工作重点包括体外和体内应用，使得能够针对性地修正或破坏致病基因。</p>
<p>其主要项目之一是 CTX001，这是一种外源性编辑细胞疗法，旨在治疗镰状细胞病和依赖输血的 β-地中海贫血，与 Vertex Pharmaceuticals 合作开发。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元于 CRISPR Therapeutics 吗？</h2>
<p>在你考虑投资 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRISPR治疗

基因改革 ETF - ARK

基因免疫&健康关怀 ETF - iShares

<p>CRISPR Therapeutics AG (NASDAQ:CRSP) 的 2028 财年每股收益预期从 Brookline Capital Markets 下调，从 7.44 美元降至 6.91 美元。该公司报告的季度每股收益为（1.28 美元），未达到预期，收入为 146 万美元。分析师对该股票的评级不一，普遍评级为 “适度买入”，目标价格为 64.53 美元。近期发生了内部人士的股票出售，机构投资者正在调整其在该股票上的持仓</p>

<ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物科技股票可能受益于专利悬崖</li>
</ul>
</div><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2028 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $6.91 per share for the year, down from their prior forecast of $7.44. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.93) per share.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免费报告) - Brookline Capital Markets 的股票研究分析师在 5 月 5 日星期二发布的研究报告中下调了对 CRISPR Therapeutics 2028 财年的每股收益预期。Brookline Capital Markets 分析师 L. Cann 现在预测该公司将发布每股收益 6.91 美元，低于之前预测的 7.44 美元。CRISPR Therapeutics 当前全年的共识预期为每股亏损 4.93 美元。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $6.06 million. CRISPR Therapeutics had a negative return on equity of 25.53% and a negative net margin of 13,856.54%.The company's revenue for the quarter was up 68.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.58) EPS.</p>
<div class="lb-trans"><p>CRISPR Therapeutics (NASDAQ:CRSP - 获取免费报告) 最近在 5 月 5 日星期二发布了季度财报。该公司报告季度每股亏损 1.28 美元，低于分析师共识预期的每股亏损 1.22 美元，差额为 0.06 美元。该季度的收入为 146 万美元，而分析师预期为 606 万美元。CRISPR Therapeutics 的股本回报率为负 25.53%，净利润率为负 13,856.54%。与去年同期相比，该季度的收入增长了 68.6%。在去年同期，该公司每股亏损 1.58 美元。</p>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在财报后上涨，管线希望增加</li>
</ul>
</div><p>A number of other brokerages have also recently commented on CRSP. Piper Sandler restated an &#34;overweight&#34; rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Bank of America dropped their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, January 22nd. Citizens Jmp dropped their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Friday, January 30th. TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a &#34;hold&#34; rating in a research report on Friday, February 13th. Finally, Morgan Stanley reaffirmed an &#34;underweight&#34; rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $64.53.</p>
<div class="lb-trans"><p>其他一些券商最近也对 CRSP 发表了评论。Piper Sandler 在 3 月 17 日星期二的研究报告中重申了 “增持” 评级，并将 CRISPR Therapeutics 的目标价从 105.00 美元上调至 110.00 美元。美国银行在 1 月 22 日星期四的研究报告中将 CRISPR Therapeutics 的目标价从 90.00 美元下调至 89.00 美元，并对该股票给予 “买入” 评级。Citizens Jmp 在 1 月 30 日星期五的研究报告中将 CRISPR Therapeutics 的目标价从 86.00 美元下调至 80.00 美元，并对该股票给予 “市场表现优于大盘” 评级。TD Cowen 在 2 月 13 日星期五的研究报告中将 CRISPR Therapeutics 的目标价从 40.00 美元上调至 45.00 美元，并给予该股票 “持有” 评级。最后，摩根士丹利在 2 月 17 日星期二的研究报告中重申了 “减持” 评级，并将 CRISPR Therapeutics 的目标价设定为 33.00 美元。一位投资分析师对该股票给予了强烈买入评级，十位给予买入评级，六位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，CRISPR Therapeutics 目前的共识评级为 “适度买入”，共识目标价为 64.53 美元。</p>
</div><p><strong>Read Our Latest Research Report on CRSP</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CRSP 的最新研究报告</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 价格表现</h2>
</div><ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
</div><p>Shares of CRSP opened at $52.38 on Wednesday. The stock's 50-day moving average is $52.41 and its two-hundred day moving average is $54.60. The stock has a market cap of $5.05 billion, a PE ratio of -8.42 and a beta of 1.74. CRISPR Therapeutics has a 12 month low of $33.03 and a 12 month high of $78.48.</p>
<div class="lb-trans"><p>CRSP 股票在星期三开盘价为 52.38 美元。该股票的 50 日移动平均线为 52.41 美元，200 日移动平均线为 54.60 美元。该股票的市值为 50.5 亿美元，市盈率为 -8.42，贝塔值为 1.74。CRISPR Therapeutics 的 12 个月低点为 33.03 美元，12 个月高点为 78.48 美元。</p>
</div><h2>Insider Transactions at CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 的内部交易</h2>
</div><p>In related news, General Counsel James R. Kasinger sold 3,182 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares of the company's stock, valued at $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 10,020 shares of the business's stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,828 shares of company stock valued at $2,578,097. 4.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席法律顾问 James R. Kasinger 于 3 月 23 日星期一出售了 3,182 股公司的股票。股票以平均价格 46.78 美元出售，总价值为 148,853.96 美元。出售完成后，首席法律顾问直接持有公司 94,308 股股票，价值 4,411,728.24 美元。此次交易使其持股减少了 3.26%。该出售在与证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Samarth Kulkarni 于 3 月 23 日星期一出售了 10,020 股公司的股票。股票以平均价格 46.78 美元出售，总价值为 468,735.60 美元。出售完成后，首席执行官直接持有公司 255,501 股股票，价值约 11,952,336.78 美元。这代表其持股减少了 3.77%。该出售的 SEC 备案提供了更多信息。在过去的九十天里，内部人士已出售 51,828 股公司股票，价值 2,578,097 美元。当前 4.10% 的股票由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>对 CRISPR Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC grew its holdings in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares during the last quarter. Thurston Springer Miller Herd &amp; Titak Inc. grew its holdings in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Optiver Holding B.V. grew its holdings in shares of CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares during the last quarter. 69.20% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Mcguire Capital Advisors Inc. 在第四季度购买了价值约 25,000 美元的 CRISPR Therapeutics 新头寸。Ramirez Asset Management Inc. 在第四季度购买了价值约 26,000 美元的 CRISPR Therapeutics 新头寸。Rothschild Investment LLC 在第四季度将其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 现在拥有 562 股公司股票，价值 29,000 美元，此前在上个季度购买了额外的 502 股。Thurston Springer Miller Herd &amp; Titak Inc. 在第四季度将其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc. 现在拥有 576 股公司股票，价值 30,000 美元，此前在上个季度购买了额外的 382 股。最后，Optiver Holding B.V. 在第三季度将其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V. 现在拥有 504 股公司股票，价值 33,000 美元，此前在上个季度购买了额外的 210 股。69.20% 的股票由机构投资者持有。</p>
</div><h2>About CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>关于 CRISPR Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG 是一家生物制药公司，专注于基于 CRISPR/Cas9 平台的基因编辑疗法的开发。该公司应用其专有技术对人类细胞中的基因进行修改，旨在为一系列严重疾病创造持久的治疗方案。其研发工作重点包括体外和体内应用，使得能够针对性地修正或破坏致病基因。</p>
</div><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p>
<div class="lb-trans"><p>其主要项目之一是 CTX001，这是一种外源性编辑细胞疗法，旨在治疗镰状细胞病和依赖输血的 β-地中海贫血，与 Vertex Pharmaceuticals 合作开发。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

FY2028 EPS Estimates for CRSP Decreased by Analyst

Market Beat

Invesco Nasdaq Biotechnology ETF

Wisdomtree BioRevolution Fund ETF

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

Piper Sandler Cos

美国银行

Citizens Financial

Toronto Dominion Bank

摩根士丹利

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

分析师下调了对 CRSP 公司 2028 财年的每股收益预期